METABOLIC SYNDROME

Full list of author information is available at the end of the articleIntroduction Cardiovascular disease (CVD) remains one of the leading causes of death with functioning graft in kidney transplant recipients [1-3]. The development of metabolic and vascu-lar complications such as post-transplant diabetes mellitus (PTDM), hypertension and dyslipidaemia has contributed to the increased risk of CVD in this population [4,5]. Abnormal glucose regulation including PTDM and pre-diabetes (impaired fasting glucose [IFG] and/or impaired glucose tolerance [IGT]) is a common complication in non-diabetic renal transplant recipients and is present in 48 to 54 % of patients at 10 weeks following kidney trans-plantation [6,7]. However, it has been shown that glucose regulation following transplantation is a dynamic process, with the incidence of PTDM and IGT declining from 54